As the Q4 2024 pharma earnings period rolls on through the first month of President Donald Trump’s second term, executives ...

Takeda's long-serving chief executive Christophe Weber has said he will retire next year, after 12 years at the Japanese drugmaker. Weber – who was briefly chief operating officer of Takeda ...

currently president of Takeda’s U.S. Business Unit, as the successor to Christophe Weber, Takeda’s president, chief executive officer (CEO) and representative director, when Mr. Weber retires from the ...

currently president of Takeda’s U.S. Business Unit, as the successor to Christophe Weber, Takeda’s president, chief executive officer (CEO) and representative director, when Mr. Weber retires ...

Takeda has been restructured under new CEO Christophe Weber, who took over in 2014 and has focused the company on cancer and specialist gastrointestinal drugs, and early stage central nervous ...

Takeda has announced a $100 million collaboration ... The Japanese pharma company, led by chief executive Christophe Weber, is looking to upgrade its R&D pipeline with some of the best cutting ...

The Japanese pharma company acquired Ariad a year ago for $5.2bn, and the latest, more modest acquisition, shows that Takeda's chief Christophe Weber sees buy-outs as ongoing route to growth.

Takeda’s CEO Christophe Weber got the deal across the line despite protests from a small but vocal group of shareholders concerned about repaying the bank loan of more than $30 billion needed to ...

She's been president of Takeda’s U.S. business for three years and prior to that she led our plasma business. While my June 2026 retirement date from Takeda is still quite a way off, now is the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Takeda has bolstered its near-term pipeline in rare haematological disorders by licensing rights to a polycythaemia vera (PV) treatment being developed by Protagonist Therapeutics. The Japanese ...